Thammahong Arsa, Puttikamonkul Srisombat, Perfect John R, Brennan Richard G, Cramer Robert A
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
Department of Microbiology, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand.
Microbiol Mol Biol Rev. 2017 Mar 15;81(2). doi: 10.1128/MMBR.00053-16. Print 2017 Jun.
Invasive fungal infections cause significant morbidity and mortality in part due to a limited antifungal drug arsenal. One therapeutic challenge faced by clinicians is the significant host toxicity associated with antifungal drugs. Another challenge is the fungistatic mechanism of action of some drugs. Consequently, the identification of fungus-specific drug targets essential for fitness remains a significant goal of medical mycology research. The trehalose biosynthetic pathway is found in a wide variety of organisms, including human-pathogenic fungi, but not in humans. Genes encoding proteins involved in trehalose biosynthesis are mechanistically linked to the metabolism, cell wall homeostasis, stress responses, and virulence of , , and . While there are a number of pathways for trehalose production across the tree of life, the TPS/TPP (trehalose-6-phosphate synthase/trehalose-6-phosphate phosphatase) pathway is the canonical pathway found in human-pathogenic fungi. Importantly, data suggest that proteins involved in trehalose biosynthesis play other critical roles in fungal metabolism and fitness that remain to be fully elucidated. By further defining the biology and functions of trehalose and its biosynthetic pathway components in pathogenic fungi, an opportunity exists to leverage this pathway as a potent antifungal drug target. The goal of this review is to cover the known roles of this important molecule and its associated biosynthesis-encoding genes in the human-pathogenic fungi studied to date and to employ these data to critically assess the opportunities and challenges facing development of this pathway as a therapeutic target.
侵袭性真菌感染会导致严重的发病和死亡,部分原因是抗真菌药物种类有限。临床医生面临的一个治疗挑战是抗真菌药物具有显著的宿主毒性。另一个挑战是某些药物的抑菌作用机制。因此,鉴定对真菌生存至关重要的真菌特异性药物靶点仍然是医学真菌学研究的一个重要目标。海藻糖生物合成途径存在于包括人类致病真菌在内的多种生物体中,但在人类中不存在。编码参与海藻糖生物合成的蛋白质的基因在代谢、细胞壁稳态、应激反应以及白色念珠菌、新生隐球菌和烟曲霉的毒力方面存在机制联系。虽然在整个生命树中有多种海藻糖产生途径,但TPS/TPP(海藻糖-6-磷酸合酶/海藻糖-6-磷酸磷酸酶)途径是在人类致病真菌中发现的经典途径。重要的是,数据表明参与海藻糖生物合成的蛋白质在真菌代谢和生存中还发挥着其他关键作用,这些作用仍有待充分阐明。通过进一步明确海藻糖及其生物合成途径成分在致病真菌中的生物学和功能,有机会将该途径作为一种有效的抗真菌药物靶点加以利用。本综述的目的是涵盖这一重要分子及其相关生物合成编码基因在迄今为止所研究的人类致病真菌中的已知作用,并利用这些数据严格评估将该途径开发为治疗靶点所面临的机遇和挑战。